Landmark MS trial launches in UK
The biggest ever trial for secondary progressive multiple sclerosis (SPMS) has kicked off in the UK at around 30 sites in England, Scotland, Wales, Northern Ireland and Eire.
14th September 2018
Latest news
US approves AZ’ hairy cell leukaemia drug
AstraZeneca and its biologics R&D arm MedImmune have bagged US approval of Lumoxiti for the treatment of hairy cell leukaemia (HCL), marking the first new treatment option in 20 years.
14th September 2018
Boehringer buys ViraTherapeutics
Boehringer Ingelheim has exercised an option to acquire all shares of oncolytic virus company ViraTherapeutics.
13th September 2018
A&E attendances in England leap 22% in a decade
The number of people visiting A&E in England has jumped by more than one-fifth in ten years, official figures show.
13th September 2018
Gilead, Precision to co-develop hepatitis B therapies
Gilead and Precision BioSciences are to work together on developing gene-editing treatments against hepatitis B.
13th September 2018
DH moves to ensure equal access to cancer drugs in NI
The Department of Health in Northern Ireland has unveiled plans to boost access to innovative new medicines for cancers and other conditions.
13th September 2018
PharmaTimes Marketer of the Year competition – last chance to enter!
Entry to the 2018 PharmaTimes Marketer of the Year competition will close on Friday 14 September.
13th September 2018
Showcase your agency's abilitity to deal with real life challenges
The highly prestigious PharmaTimes Communications Team of the Year competition will close for entry at midnight on Friday. Take this opportunity to compete alongside other healthcare agencies in a one-off challenge to shape real-life solutions for one of the UK's leading charities.
12th September 2018
Gilead, Galapagos’ filgotinib hits goals in RA trial
Gilead and Galapagos have unveiled another set of promising data for JAK inhibitor filgotinib, this time in rheumatoid arthritis.
12th September 2018
MSD to file antibiotic Zerbaxa for pneumonia
MSD is gearing up to file antibiotic Zerbaxa on both sides of the Atlantic for certain forms of pneumonia on the success of a late-stage trial backing its safety and efficacy.
12th September 2018
MHRA permits cell/gene therapy production at CGT Catapult site
The production of new cell and gene therapies at a manufacturing site in Stevenage - for use in health services around the world - has been given the green light by the Medicines and Healthcare products Regulatory Agency (MHRA).
12th September 2018
Merck, Pfizer intend to file Bavencio, Inlyta combo
Merck KGaA and Pfizer say they intend to seek US approval of a combination of Bavencio and Inlyta for kidney cancer on the back of progression-free survival data from a late-stage trial.
12th September 2018
Shire’s Veyvondi approved in Europe for bleeding disorder
European regulators have approved Shire’s von Willebrand Disease therapy Veyvondi.
12th September 2018
Four new medicines available via NHS Scotland
The Scottish Medicines Consortium has cleared funds for use of four new medicines by NHS Scotland, including Sanofi’s biologic Dupixent for dermatitis.
11th September 2018
EC green-lights MSD’s Keytruda combo for lung cancer
The European Commission has approved MSD’s Keytruda for use in combination with Eli Lilly’s Alimta and platinum-based chemotherapy for the first-line treatment of some advanced lung cancers.
11th September 2018
